J
J C Schwartz
Researcher at French Institute of Health and Medical Research
Publications - 12
Citations - 4625
J C Schwartz is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Dopamine receptor D3 & Dopamine receptor D2. The author has an hindex of 9, co-authored 12 publications receiving 4525 citations.
Papers
More filters
Journal ArticleDOI
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
TL;DR: The D3 receptor is localized to limbic areas of the brain, which are associated with cognitive, emotional and endocrine functions, and seems to mediate some of the effects of antipsychotic drugs and drugs used against Parkinson's disease.
Journal ArticleDOI
Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.
Marie-Louise Bouthenet,Evelyne Souil,Marie-Pascale Martres,Pierre Sokoloff,Bruno Giros,J C Schwartz +5 more
TL;DR: D2 and D3 receptor mRNAs were also detected at the level of the substantia nigra, suggesting that these receptors function as both autoreceptor and postsynaptic receptors, the latter being most abundant in dopaminergic areas known to be associated with cognitive and emotional functions.
Journal ArticleDOI
Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.
D. Levesque,Jorge Diaz,C. Pilon,Marie-Pascale Martres,Bruno Giros,Evelyne Souil,D Schott,J L Morgat,J C Schwartz,Pierre Sokoloff +9 more
TL;DR: Native D3 receptors in brain are characterized by an unusually high nanomolar affinity for dopamine and a low modulatory influence of guanyl nucleotides on agonist binding, which suggest that D3 receptor are involved in a peculiar mode of neurotransmission in a restricted subpopulation of dopamine neurons.
Journal ArticleDOI
Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
TL;DR: The results suggest that the activity of recently developed antiparkinsonian drugs at either the dopamine D1 or the serotonin D3 and not only the dopamineD2 receptors should be taken into account in analyses of their mechanisms of action in therapeutics.
Journal ArticleDOI
D3 receptor test in vitro predicts decreased cocaine self-administration in rats.
TL;DR: The hypothesis that the D3 receptor may be an important target for pharmacotherapies for cocaine abuse and dependence is supported.